Pfizer COVID-19 Vaccine Delayed Until At Least Late November
Oct 18 2020
Dozens of companies, from biotech start-ups to Big Pharma, are racing to develop a safe and effective COVID-19 vaccine, because the world needs it and for the potential pay day.
American pharmaceutical giant Pfizersaid on Friday it would apply for emergency authorisation in the USA for its vaccine in late November if safety data pans out.
Young people may have to wait until 2022 to receive a coronavirus vaccine, the chief scientist at the World Health Organisation (WHO) has said.
Shah said that's just one of the distribution challenges, but nevertheless, they are working out scenarios based on the vaccines now in late-stage trials. That, according to the Pfizer CEO's letter, is now the gating step for the approval of a vaccine.
Pfizer's predictions mean that its vaccine, called BNT162b2, may not be ready before the U.S. elections, as the president of the country, Donald Trump, had said on occasion, who stated that he expected this drug, of which he has already reserved 100 million doses, would be the first to be approved in the United States. "This means we may know whether or not our vaccine is effective by the end of October", he said.
For an emergency use application, the FDA is requiring at least two months of safety data on half of the trial participants after their final vaccine doses, according to a guidance document released last week.
The company said it hopes to move ahead with the vaccine after safety data is available in the third week of November.
Authorities did not say how many people in the city had been given the vaccine, which comes in two doses, administered up to 28 days apart and costing a total of 400 yuan (50 Euro).
The federal government will be responsible for giving money to North Carolina's state, tribal and local health departments.
The list also includes Tribal nations and Tribal health organizations, health care organizations, industry groups, policymakers, immunization coalitions and community vaccination providers to share information on the vaccine distribution plan.
Similar studies in recent weeks have reported on one of the Russian vaccines, along with those from the University of Oxford, Chinese company CanSino, and Moderna. She said there are about 11 vaccines worldwide in late-stage testing, and another 200 candidates under development. "We look forward to working with our partners to providing the COVID-19 vaccine to the public and to helping ensure the health and safety of our community". "People are going to be shocked that they'll be asked to wear the mask continually, even after it's distributed".